TRPV2 and cancer: Xenograft tumor-based in vivo approaches in cancer prostate cells suggest that TRPV2 silencing diminishes the weight of tumors and the expression of invasion markers, namely MMP2, MMP9 and cathepsine B (Monet et al., 2010).